ArticleEmerging microbes & infections2026
An ECSA-lineage chikungunya outbreak in Foshan, China: age-stratified clinical and virological profiles.
Article in Emerging microbes & infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Detection and genomic characterization of a travel-associated ECSA lineage chikungunya virus infection in Mexico.ASM case reports · 2026Article
- Predictive association between control measures and chikungunya fever incidence based on random forest and SHAP analysis.PLoS neglected tropical diseases · 2026Article
- A single-dose chimeric Newcastle disease virus (NDV)/chikungunya virus (CHIKV) is an effective CHIKV vaccine candidate.Journal of virology · 2026Article
- Epidemic features and potential impact of vaccine campaigns on the 2025 chikungunya outbreak in southern China: a mathematical modelling study.New microbes and new infections · 2026Article
- Genomic epidemiology reveals the origins and transmission dynamics of chikungunya virus in China.Infectious diseases of poverty · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since July 2025, Foshan has experienced the largest outbreak of Chikungunya fever in China. This single-centre retrospective study included 1,908 laboratory-confirmed cases. Phylogenetic analysis identified the East/Central/South African lineage, closely related to the 2025 La Réunion strain. The included cases were all non-severe, showed no sex bias, but exhibited clear regional clustering. Fever (86.8%), arthralgia (85.4%), and rash (64.1%) were predominant symptoms. Fever and rash were more common in minors, while arthralgia increased with age. Lymphopenia occurred in 65.5% of patients and was more common in elderly patients, who had higher viral loads and longer RNA clearance times. Age, sex and viral load independently influenced clinical manifestations and laboratory characteristics. The findings provide initial descriptive evidence and highlight age-related differences in chikungunya's clinical and virological profiles. Long-term follow-up and larger-scale investigations were necessary to provide evidence for clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.